



111 RIVER STREET, HOBOKEN, NJ 07030

*****IMMEDIATE RESPONSE REQUIRED*****

Your article will be published online via Wiley's EarlyView service (wileyonlinelibrary.com) shortly after receipt of corrections. EarlyView is Wiley's online publication of individual articles in full-text HTML, and/or pdf format before release of the compiled print issue of the journal. Articles posted online in EarlyView are peer-reviewed, copyedited, author corrected, and fully citable. EarlyView means you benefit from the best of two worlds – fast online availability as well as traditional, issue-based archiving.

☐ **READ PROOFS CAREFULLY**

- This will be your only chance to review these proofs.
- Please note that the volume and page numbers shown on the proofs are for position only.

☐ **ANSWER ALL QUERIES ON PROOFS** (Queries for you to answer are attached as the last page of your proof.)

- Please mark all corrections clearly. Note that excessive author alterations may ultimately result in delay of publication and extra costs may be charged to you.

☐ **CHECK FIGURES AND TABLES CAREFULLY**

- Check size, numbering, and orientation of figures.
- All images in the PDF are downsampled (reduced to lower resolution and file size) to facilitate Internet delivery. These images will appear at higher resolution and sharpness in the printed article.
- Review figure legends to ensure that they are complete.
- Check all tables. Review layout, title, and footnotes.

☐ **ADDITIONAL COPIES**

- If you wish to purchase additional copies of the journal in which your article appears, please contact cs-journals@wiley.com

Send the corrected proof's pdf file by email attachment (or scan, or fax the proof) to:

Larry Graup,
Wiley-Blackwell Journal Production
610 Bear Creek Street,
Auburn, PA 17922 USA
E-mail: lgraup@infionline.net
Phone: **570-754-3060**

RETURN IMMEDIATELY AS YOUR ARTICLE WILL BE POSTED IN ORDER OF RECEIPT. YOU CAN EXPECT TO SEE YOUR ARTICLE ONLINE SHORTLY AFTER RECEIPT OF CORRECTIONS.



Additional reprint purchases

Should you wish to purchase additional copies of your article, please click on the link and follow the instructions provided:

<https://caesar.sheridan.com/reprints/redir.php?pub=10089&acro=CYTOA>

Corresponding authors are invited to inform their co-authors of the reprint options available.

Please note that regardless of the form in which they are acquired, reprints should not be resold, nor further disseminated in electronic form, nor deployed in part or in whole in any marketing, promotional or educational contexts without authorization from Wiley. Permissions requests should be directed to mail to: permissionsus@wiley.com


For information about 'Pay-Per-View and Article Select' click on the following link: wileyonlinelibrary.com/aboutus/ppv-articleselect.html

USING e-ANNOTATION TOOLS FOR ELECTRONIC PROOF CORRECTION


Required software to e-Annotate PDFs: Adobe Acrobat Professional or Adobe Reader (version 11 or above). (Note that this document uses screenshots from Adobe Reader DC.)
The latest version of Acrobat Reader can be downloaded for free at: <http://get.adobe.com/reader/>

Once you have Acrobat Reader open on your computer, click on the [Comment](#) tab (right-hand panel or under the Tools menu).


This will open up a ribbon panel at the top of the document. Using a tool will place a comment in the right-hand panel. The tools you will use for annotating your proof are shown below:




1. **Replace (Ins)** Tool – for replacing text.


 Strikes a line through text and opens up a text box where replacement text can be entered.

How to use it:


- Highlight a word or sentence.
- Click on .
- Type the replacement text into the blue box that appears.



2. **Strikethrough (Del)** Tool – for deleting text.

 Strikes a red line through text that is to be deleted.



How to use it:

- Highlight a word or sentence.
- Click on .
- The text will be struck out in red.



experimental data if available. For ORFs to be had to meet all of the following criteria:


1. Small size (35-250 amino acids).
2. Absence of similarity to known proteins.
3. Absence of functional data which could not be the real overlapping gene.
4. Greater than 25% overlap at the N-terminus with another coding feature; over both ends; or ORF containing a tRNA.

3. **Commenting** Tool – for highlighting a section to be changed to bold or italic or for general comments.


  Use these 2 tools to highlight the text where a comment is then made.

How to use it:


- Click on .
- Click and drag over the text you need to highlight for the comment you will add.
- Click on .
- Click close to the text you just highlighted.
- Type any instructions regarding the text to be altered into the box that appears.




4. **Insert** Tool – for inserting missing text at specific points in the text.


 Marks an insertion point in the text and opens up a text box where comments can be entered.

How to use it:


- Click on .
- Click at the point in the proof where the comment should be inserted.
- Type the comment into the box that appears.



5. **Attach File** Tool – for inserting large amounts of text or replacement figures.

 Inserts an icon linking to the attached file in the appropriate place in the text.


How to use it:

- Click on  .
- Click on the proof to where you'd like the attached file to be linked.
- Select the file to be attached from your computer or network.
- Select the colour and type of icon that will appear in the proof. Click OK.


The attachment appears in the right-hand panel.

chondrial preparator
ative damage injury
e extent of membra
i, malondialdehyde (TBARS) formation. I
used by high perform

6. **Add stamp** Tool – for approving a proof if no corrections are required.


 Inserts a selected stamp onto an appropriate place in the proof.

How to use it:

- Click on  .
- Select the stamp you want to use. (The **Approved** stamp is usually available directly in the menu that appears. Others are shown under *Dynamic*, *Sign Here*, *Standard Business*).
- Fill in any details and then click on the proof where you'd like the stamp to appear. (Where a proof is to be approved as it is, this would normally be on the first page).

of the business cycle, starting with the
on perfect competition, constant ret
production. In this environment goods
extra profits and hence a transfer of market
he market for the good is determined by the model. The New-Key
otaki (1987), has introduced produc
general equilibrium models with nomin
and demand shocks. Most of this literat

APPROVED




Drawing tools available on comment ribbon

How to use it:


- Click on one of the shapes in the **Drawing Markups** section.
- Click on the proof at the relevant point and draw the selected shape with the cursor.
- To add a comment to the drawn shape, right-click on shape and select *Open Pop-up Note*.
- Type any text in the red box that appears.

7. **Drawing Markups** Tools – for drawing shapes, lines, and freeform annotations on proofs and commenting on these marks.

Allows shapes, lines, and freeform annotations to be drawn on proofs and for comments to be made on these marks.



For further information on how to annotate proofs, click on the **Help** menu to reveal a list of further options:





International Society for Advancement of Cytometry

www.isac-net.org

2014 ISAC MEMBERSHIP APPLICATION

Please include current telephone number, fax and e-mail address on back of form. Make any address changes on back of form.

Membership Dues for Calendar Year 2014

You can join ISAC online at www.isac-net.org. To ensure proper crediting of dues and processing of journals please remit dues promptly. Options below include Cytometry Part A. Individual subscriptions to the journals are for personal or laboratory use only and not for institutional use. Please note that if you join after October 1, 2014, subscriptions will not begin until January 2015.

	Cost	Enter Amount
Full Member with print and electronic journal access	\$126 (or see sliding country scale on reverse page)	\$
Three-year membership	\$378 (or 3 times the reduced sliding scale rate)	\$
Full Member with electronic journal access only	\$100 (or see sliding country scale on reverse page)	\$
Three-year membership	\$300 (or 3 times the reduced sliding scale rate)	\$

Additional Memberships & Subscriptions

Renewing International Clinical Cytometry Society (ICCS) members will receive a renewal notice directly from ICCS; do not renew your ICCS membership through ISAC. Individual subscriptions to the journals are for personal or laboratory use only and not for institutional use.

	Cost	Enter Amount
Membership in ICCS: Incl. 6 print issues & e-access to <i>Cytometry Part B: Clinical Cytometry</i>	\$ 95.00	\$
Electronic Membership in ICCS Electronic access only to <i>Cytometry Part B: Clinical Cytometry</i>	\$ 75.00	\$

The options below are available only with ISAC Membership:

ISAC members receive a 20% discount on an individual online subscription to *Current Protocols in Cytometry*. Please contact protocol@wiley.com and mention code **ISAC3** in the subject line, or call 800-825-7550 (USA) or 1-317-572-3983 (outside the USA).

Subscription to <i>Cytometry Part B: Clinical Cytometry</i> . Includes six print issues and online access.	\$ 64.00	\$
Subscription to <i>Cytometry Part B: Clinical Cytometry</i> . Online access only.	\$ 50.00	\$
The ISAC Cytometry CLIA Compliance Manual. Print version; online access is free.	\$ 18.00	\$

Payment Options

Return this invoice with payment in the form of credit card, check or money order. **All subscriptions and renewals must be paid in U.S. funds. Checks or money orders must be drawn on a U.S. Bank with the MICR encoded number on the bottom of the check.** Make checks payable to: ISAC or International Society for Advancement of Cytometry. Purchase orders, stamps or coupons are NOT accepted as a form of payment. Membership dues to ISAC cannot be deducted as charitable contributions, but may be deductible for federal income tax purposes as ordinary and necessary business expenses. Consult your tax advisor for individual assistance in specific situations. ISAC Federal Tax ID: 85-0319221.

Total Amount from Above (Dues, Donations, Memberships and Subscriptions) \$

Bank/Wire Transfers (Contact ISAC for bank transfer information. Name or member ID# must appear on transfer. All originating bank fees must be pre-paid.)

Originating Bank _____ Date of Transfer _____
Bank Wire Transfer _____ Add handling fee of \$25.00 \$

Maryland or District of Columbia Residents: Please add 6% sales tax or provide Tax Exempt Number _____ \$

Canadian Subscriptions: GST of 5% must be added to total payment. Please include the GST number if available. The price for Canada, Mexico and other international subscriptions includes postage. _____ GST Number _____ \$

Total Payment Enclosed \$

Credit Card Information Credit card orders may be faxed to: 301-634-7099 ☐ American Express ☐ VISA ☐ Master Card ☐ Discover

Card Number _____ Name on Card _____

Expiration Date _____ 3 or 4 Digit CVV# _____

Authorized Signature _____

ISAC, Attn: Dues & Subscriptions • 9650 Rockville Pike • Bethesda, Maryland 20814-3998 USA
Telephone (301) 634-7435 • Fax (301) 634-7099 • Email: membership@isac-net.org

Membership Profile (Please revise or add information as appropriate)

Degree

- ☐ Ph.D.
☐ M.D.
☐ M.A.
☐ M.S.
☐ B.A.
☐ B.S.
☐ Associate
☐ Other _____

Field of Study

- ☐ Biological Sciences
☐ Chemical Sciences
☐ Computer Sciences
☐ Engineering
☐ Medicine
☐ Physical Sciences
☐ Other _____

Research Areas

- ☐ Biochemistry
☐ Biophysics
☐ Biotechnology
☐ Cell & Molecular Biology
☐ Cell Physiology
☐ Clinical Lab Practice
☐ Clinical Research
☐ Flow & Image Cytometry
☐ Genetics
☐ Immunology
☐ Instrumental Development
☐ Microbiology
☐ Pathology
☐ Plant Biology
☐ Other _____

Interest Groups

Check to be associated with one or more of the following groups:

- ☐ Biological Cytometry Group
☐ Clinical Cytometry Group
☐ Cytometric Technology Group
☐ Core Managers
☐ Microparticles
☐ Stem Cells

Please indicate if there is a particular interest group you would like to see:

- ☐ _____
☐ _____

To serve you better with more targeted information and programs, please answer the following new ISAC demographic questions:

What is your institutional setting?

- ☐ University
☐ Medical School
☐ Hospital
☐ Out-Patient Clinic
☐ Pharmaceutical Company
☐ Biotechnology Company
☐ Testing Laboratory
☐ Non-Profit
☐ Government
☐ Other _____

What is your title/job description?

- ☐ Professor/Principal/Investigator
☐ Post-doc
☐ Core Facility Manager
☐ Core Facility Tech
☐ Graduate Student
☐ Undergraduate Student
☐ President/CEO
☐ VP
☐ Director
☐ Senior Scientist
☐ Scientist
☐ Technician
☐ Physician (Resident/Sr. Resident/Attending)
☐ Consultant

Contact Information & Address Changes

Please provide the following information for changes only:

Phone: _____ FAX: _____

Name: _____

Email: _____

Address: _____

City: _____ State/Province: _____ Zip/Postal Code: _____

2014 ISAC Member Dues Sliding Country Rates

Residents of the following countries pay the full rate. Full membership with print and electronic journal access pays \$126 for one year or \$378 for three years.

Full membership with electronic journal access only pays \$100 for one year or \$300 for three years.

Andorra	Canada	Faeroe Islands	Isle of Man	Malta	Qatar	Sweden
Antigua & Barbuda	Cayman Islands	Finland	Israel	Monaco	Russian Federation	Switzerland
Aruba	Channel Islands	France	Italy	Netherlands	San Marino	Taiwan
Australia	Chile	French Polynesia	Japan	New Caledonia	Saudi Arabia	Trinidad and Tobago
Austria	Croatia	Germany	Korea, Rep.	New Zealand	Singapore	Turks and Caicos Islands
Bahamas, The	Curacao	Greece	Kuwait	N. Mariana Islands	Sint Maarten	United Arab Emirates
Bahrain	Cyprus	Greenland	Latvia	Norway	Slovak Republic	United Kingdom
Barbados	Czech Republic	Guam	Liechtenstein	Oman	Slovenia	United States
Belgium	Denmark	Hong Kong SAR, China	Lithuania	Poland	Spain	Uruguay
Bermuda	Estonia	Iceland	Luxembourg	Portugal	St. Kitts and Nevis	Virgin Islands (U.S.)
Brunei Darussalam	Equatorial Guinea	Ireland	Macao SAR, China	Puerto Rico	St. Martin	

Residents of the following countries pay \$110 for one year or \$330 for three years for full membership with print and electronic journal access.

Full membership with electronic journal access only pays \$84 per year or \$252 for three years.

Albania	Bosnia & Herzegovina	Dominica	Iraq	Maldives	Peru	Thailand
Algeria	Botswana	Dominican Republic	Jamaica	Marshall Islands	Romania	Tonga
American Samoa	Brazil	Ecuador	Jordan	Mauritius	Serbia	Tunisia
Angola	Bulgaria	Fiji	Kazakhstan	Mexico	Seychelles	Turkey
Argentina	China	Gabon	Lebanon	Montenegro	South Africa	Turkmenistan
Azerbaijan	Colombia	Grenada	Libya	Namibia	St. Lucia	Tuvalu
Belarus	Costa Rica	Hungary	Macedonia, FYR	Palau	St. Vincent/Grenadines	Venezuela, RB
Belize	Cuba	Iran, Islamic Rep.	Malaysia	Panama	Suriname	

Residents of the following countries pay \$94 for one year or \$282 for three years for full membership with print and electronic journal access.

Full membership with electronic journal access only pays \$68 for one year or \$204 for three years.

Armenia	Djibouti	Honduras	Mauritania	Pakistan	Solomon Islands	Uzbekistan
Bhutan	Egypt, Arab Rep.	Indonesia	Micronesia, Fed. Sts.	Papua New Guinea	Sri Lanka	Vanuatu
Bolivia	El Salvador	India	Moldova	Paraguay	Sudan	Vietnam
Cameroon	Georgia	Kiribati	Mongolia	Philippines	Swaziland	West Bank and Gaza
Cape Verde	Ghana	Kosovo	Morocco	Samoa	Syrian Arab Republic	Yemen, Rep
Congo, Rep.	Guatemala	Lao PDR	Nicaragua	Sao Tome & Principe	Timor-Leste	Zambia
Cote d'Ivoire	Guyana	Lesotho	Nigeria	Senegal	Ukraine	

Residents of the following countries pay \$78 for one year or \$234 for three years for full membership with print and electronic journal access.

Full membership with electronic journal access only pays \$52 for one year or \$156 for three years.

Afghanistan	Cambodia	Eritrea	Haiti	Madagascar	Nepal	South Sudan
Bangladesh	Central African Republic	Ethiopia	Kenya	Malawi	Niger	Tajikistan
Benin	Chad	Gambia, The	Korea, Dem. Rep.	Mali	Rwanda	Tanzania
Burkina Faso	Comoros	Guinea	Kyrgyz Republic	Mozambique	Sierra Leone	Togo
Burundi	Congo, Dem. Rep.	Guinea-Bissau	Liberia	Myanmar	Somalia	Uganda
						Zimbabwe

Dear *Cytometry* Contributor:

Thank you for publishing in *Cytometry*. Because you recognize the value and importance of this journal as a venue for publishing your work, we invite you to join the International Society for Advancement of Cytometry (ISAC).

One of the many benefits of membership in this esteemed society is that ISAC members now receive a 50% discount on reprint orders for *Cytometry*. Membership also guarantees that you will receive this publication at an astonishingly low price!

With *Cytometry*, you will get unmatched coverage of cytometric and bioimaging techniques in basic and applied biomedical research. The journal embraces all aspects of analytical cytology - from molecular biology, through cytochemistry, cytophysics and cell biology - pathology and physiology to statistics and instrumentation. *Clinical Cytometry*, the bimonthly section of *Cytometry*, reports on the use of flow and image cytometry in a clinical setting and is available for a nominal addition to your regular ISAC membership fee.

In fact, we feel that many of your colleagues could benefit from *Cytometry*'s in-depth scientific coverage and desktop delivery of valuable data but they might not be ISAC members. Accessing the journal could be problematic for non-ISAC members if your library does not subscribe. Now you can help ensure that your colleagues have all the latest information they need to conduct their research thoroughly and effectively. Just make sure your library has *Cytometry* and with it, *Clinical Cytometry* (a total of 18 issues per year) on the shelves and on-line. For more information, direct your librarians to www.wiley.com/cytometry, or call 1-800-879-4539.

If your library subscribes to *Cytometry*, you and your colleagues can now browse the full text of each issue on-line. Full text on-line gives you faster, desktop accessing of research findings, flexible search capabilities, and fully downloadable information. To learn more about how to get your library registered, please visit *Wiley Online Library* (www.wileyonlinelibrary.com) This Internet tool makes *Cytometry* a more cutting-edge resource than ever before.

Regards,
John Wiley & Sons, Inc.



111 RIVER STREET, HOBOKEN, NJ 07030

ANNOUNCEMENT

NEW TO CYTOMETRY AND CLINICAL CYTOMETRY

Online Submission and Peer Review

In taking a step toward facilitating online collaboration and expediting the publication process, *CYTOMETRY* and *CLINICAL CYTOMETRY* are pleased to now offer web-based submission and peer review. The online submission site offers new functionality not offered before, including:

- Instant confirmation of manuscript receipt
- The ability to track a manuscript's progress through the peer review process
- The ability to submit manuscripts 24/7 from anywhere in the world, via web access

We invite authors to visit the online submission site at
<http://cyto-wiley.manuscriptcentral.com/>.

To submit manuscript online, please:

1. Prepare your manuscript and illustrations in appropriate format, according to the instructions given at <http://cyto-wiley.manuscriptcentral.com/> under the "Instructions and Forms" button. Please also be sure that your paper conforms to the scientific and style instructions of the Journal.
2. If you have not already done so, create an account for yourself in the system at the submission site: <http://cyto-wiley.manuscriptcentral.com/> by clicking on the "Create an Account" button. To monitor the progress of your manuscript through the review process, just login periodically and check your Author Center.
3. Please be sure to study the *Instructions and Forms* at the site carefully, and then let the system guide you through the submission process. Online help is available to you at all times during the process. You are also able to exit/re-enter at any stage before finally "submitting" your manuscript. All submissions are kept strictly confidential. If you have any questions, do not hesitate to contact us at edsupport@wiley.com

Color reproduction in your *Cytometry Part A* article

Color figures were included with the final manuscript that we received for your article. Due to the high cost of color printing, we can only print figures in color if authors cover the expense.

Color printing costs \$500. per page regardless of the number of color figures on a page.

Please indicate if you would like your figures to be printed in color or black and white. Color images will be reproduced online in WileyOnlineLibrary at no charge, whether or not you opt for color printing

Failure to return this form will result in publication of your figures in black and white.

Journal : **CYTOMETRY PART A**

Volume:

Issue:

Title of Manuscript:

Manus number:

Author(s):

Number of color pages:

Number of color pages	Color charges	Number of color pages	Color charges
1	500	6	3000
2	1000	7	3500
3	1500	8	4000
4	2000	9	4500
5	2500	10	5000

Please contact the production editor if you have more than 10 pages of color.

☐ Please print my figures in black and white

☐ Please print my figures in color:

Total \$

International orders must be paid in currency and drawn on a U.S. bank

Bill to:

Name

Address

--

Fax:

Phone :

Email:

WILEY

Author Query Form

Journal: CYTO

Article: 23186

Dear Author,

During the copyediting of your manuscript the following queries arose.

Please refer to the query reference callout numbers in the page proofs and respond to each by marking the necessary comments using the PDF annotation tools.

Please remember illegible or unclear comments and corrections may delay publication.

Many thanks for your assistance.

Query References	Query	Remarks?
AQ1	AUTHOR: Please check whether short title is OK as typeset.	
AQ2	AUTHOR: Please check whether the footnote is OK as typeset.	
AQ3	AUTHOR: Please note that Refs. [9 and 56] are duplicate references and hence [56] has been deleted and renumbering has been done to maintain sequential order.	
AQ4	AUTHOR: Author: Are any of the authors contributing to this work supported as an ISAC Scholar? If yes, please include in the Acknowledgments section: "Author First Name Last Name was supported as an ISAC Scholar." Are any of the authors contributing to this work a member of ISAC's Shared Resource Lab (SRL) Emerging Leaders? If yes, please include in the Acknowledgments section: "Author First Name Last Name is an ISAC Shared Resource Lab Emerging Leader."	
AQ5	AUTHOR: Please check whether the edit made in Ref. [2] is OK as typeset.	
AQ6	AUTHOR: Journal style is to generally list 10 authors followed by et al. Please replace "et al." in References with missing author names for less than 10 author names.	
AQ7	AUTHOR: Please provide page range for Ref. [17].	
AQ8	AUTHOR: Please provide volume number for Refs. [30, 41].	
AQ9	AUTHOR: Please provide author details for Ref. [50].	
AQ10	AUTHOR: Author, if you want the color figures to be printed in color, please inform the editor when you return materials. The cost of color printing is \$500 per color page (by the page, not by the number of figures on a page). There is no cost to you for online color only.	

AQ11	AUTHOR: Please confirm that given names (red) and surnames/family names (green) have been identified correctly.	
------	---	--

Funding Info Query Form

Please confirm that the funding sponsor list below was correctly extracted from your article: that it includes all funders and that the text has been matched to the correct FundRef Registry organization names. If a name was not found in the FundRef registry, it may be not the canonical name form or it may be a program name rather than an organization name, or it may be an organization not yet included in FundRef Registry. If you know of another name form or a parent organization name for a “not found” item on this list below, please share that information.

FundRef name	FundRef Organization Name
The PetPlan Charitable Trust	[NOT FOUND IN FUNDREF REGISTRY]

WILEY
Author Proof



Cryopreservation of Canine Cardiosphere-Derived Cells: Implications for Clinical Application

AQ11

Luke C. Dutton,^{1*} Sophie A.V. Church,¹ Hannah Hodgkiss-Geere,² Brian Catchpole,³ Anthony Huggins,³ Jayesh Dudhia,^{1†} David J. Connolly^{1†}

¹Department of Clinical Science and Services, Royal Veterinary College, University of London, London, UK

²Department of Veterinary Clinical Science, University of Liverpool, Liverpool, UK

³Department of Pathobiology and Population Sciences, Royal Veterinary College, University of London, London, UK

Received 12 April 2017; Revised 27 June 2017; Accepted 18 July 2017

Grant sponsor: The PetPlan Charitable Trust, Grant number: Project number: 214–252

Additional supporting information may be found in the online version of this article at the publisher's web-site

*Correspondence to: Luke C. Dutton, Clinical Science and Services, Royal Veterinary College, Hawkshead Lane, North Mymms, Hatfield, Herts AL9 7TA, UK. Email: lcdutton@rvc.ac.uk
Senior authors

Published online 00 Month 2017 in Wiley Online Library (wileyonlinelibrary.com)

DOI: 10.1002/cyto.a.23186

© 2017 International Society for Advancement of Cytometry

Abstract

The clinical application of cardiosphere-derived cells (CDCs) to treat cardiac disease has gained increasing interest over the past decade. Recent clinical trials confirm their regenerative capabilities, although much remains to be elucidated about their basic biology. To develop this new treatment modality, in a cost effective and standardized workflow, necessitates the creation of cryopreserved cell lines to facilitate access for cardiac patients requiring urgent therapy. Cryopreservation may however lead to alterations in cell behavior and potency. The aim of this study was to investigate the effect of cryopreservation on canine CDCs. CDCs and mesenchymal stem cells (MSCs) isolated from five dogs were characterized. CDCs demonstrated a population doubling time that was unchanged by cryopreservation (fresh vs. cryopreserved; 57.13 ± 5.27 h vs. 48.94 ± 9.55 h, $P = 0.71$). This was slower than for MSCs (30.46 h, $P < 0.05$). The ability to form clones, self-renew, and commit to multiple lineages was unaffected by cryopreservation. Cryopreserved CDCs formed larger cardiospheres compared to fresh cells ($P < 0.0001$). Fresh CDCs showed a high proportion of $CD105^+$ ($89.0\% \pm 4.98$) and $CD44^+$ ($99.68\% \pm 0.13$) cells with varying proportions of $CD90^+$ ($23.36\% \pm 9.78$), $CD34^+$ ($7.18\% \pm 4.03$) and $c\text{-Kit}^+$ ($13.17\% \pm 8.67$) cells. $CD45^+$ ($0.015\% \pm 0.005$) and $CD29^+$ ($2.92\% \pm 2.46$) populations were negligible. Increasing passage number of fresh CDCs correlated with an increase in the proportion of $CD34^+$ and a decrease in $CD90^+$ cells ($P = 0.003$ and 0.03 , respectively). Cryopreserved CDCs displayed increased $CD34^+$ ($P < 0.001$) and decreased $CD90^+$ cells ($P = 0.042$) when compared to fresh cells. Overall, our study shows that cryopreservation of canine CDCs is feasible without altering their stem characteristics, thereby facilitating their utilization for clinical trials. © 2017 International Society for Advancement of Cytometry

Key terms

cardiosphere-derived cells; canine; cryopreservation; differentiation; stem cells

AQ2

NON-ischemic dilated cardiomyopathy (DCM) is the second most common cardiac disease of dogs, accounting for 10% of canine cardiac diagnoses (1). DCM is a heterogeneous disease of the canine myocardium that demonstrates breed specific characteristics at pathological and clinical levels (2). An underlying genetic basis has been proposed in a number of breeds, including the Doberman and Boxer, where the disease has been studied in detail and shown to be both common and severe with a cumulative prevalence in European Dobermans >8 years of age of 44% (2–7). Two distinct histopathological variations of canine DCM have been described; attenuated wavy fiber type and fibro-fatty infiltration type (7). Fibro-fatty infiltration is considered analogous to arrhythmogenic right ventricular cardiomyopathy (ARVC) in humans because of the comparable pathological changes and clinical presentation between the two species (8–12). Although the pathophysiologic mechanism underlying ARVC remains unclear, it is thought to include molecular pathways involved in

ORIGINAL ARTICLE

the formation of mechanical and electrical coupling, apoptosis, and migration and differentiation of epicardial-derived cells (13). The electrical uncoupling together with fibro-fatty replacement of the myocardium are considered primary substrates for arrhythmia and sudden cardiac death is a frequent consequence (10). Dogs that survive develop progressive ventricular dilation and systolic dysfunction leading to congestive heart failure (12,14). Similar to humans, treatment options are limited and directed toward controlling clinical signs but do not promote myocardial repair or ultimately reduce disease progression.

Since the discovery that the adult heart had regenerative ability there has been increasing interest in the therapeutic use of adult cardiac stem cells (15,16). Multiple populations of cardiac progenitor cells have been isolated, such as side population cells, stem-cell antigen positive cells (Sca-1⁺), c-Kit⁺ (also known as CD117) cells, Islet-1⁺ cells, cardiospheres, and cardiosphere-derived cells (CDCs) (17–23). CDCs in particular have drawn much attention since there is mounting evidence they contribute to myocardial repair (22,24–27). Phase 1 clinical trials in humans have shown improved cardiac function using autologous CDCs (28,29). Allogeneic CDC therapy was shown to be safe, with marginal improvement in cardiac function, in a small clinical trial in Dobermans with DCM; however, there was no increase in survival time (30).

CDCs represent a heterogeneous cardiac stem cell population with the ability to form clones, self-renew and commit to multiple lineages including smooth muscle, myocardium, and endothelium (25,31,32). CDCs are isolated from an intermediate cell population of cardiospheres which have been generated using various methods, including plating of cardiac outgrowth cells on poly-D-lysine coated wells (21,33), the use of forced aggregation on low attachment surfaces (25,30), aggregation plates and the hanging drop method (32). Cardiospheres are then cultured on plastic to form a monolayer of CDCs, which can be readily passaged and expanded to clinically useful cell numbers (28).

The development of a cost effective and efficient clinical treatment would necessitate the creation of cell banks for allogeneic applications, where cardiac stem cells from donor dogs could be cultured, characterized, assessed for endotoxins, purity, and subsequently cryopreserved. The aim of this work was to investigate the immunophenotype and basic cellular characteristics of canine CDCs prior to and following cryopreservation.

MATERIALS AND METHODS

Tissue Preparation

Canine tissue was obtained immediately post-mortem from five cadavers with owners' informed consent following approval by the Royal Veterinary College Ethics and Welfare Committee (Approval number: URN 2013 1246). Donors were aged 0.5, 4, 5, 5, and 6 years. Full thickness atrial tissue was aseptically removed and placed in chilled cardiac explant medium (CEM) consisting of Iscove's Modified Dulbecco's Medium (IMDM), 10% fetal bovine serum (FBS), 1% L-

glutamine, 1% penicillin-streptomycin (P/S) (all from Thermo Fisher Scientific), and 0.1 mmol/l 2-mercaptoethanol (2-ME) (Sigma-Aldrich). Subcutaneous adipose tissue was harvested from the popliteal region and placed in mesenchymal stem cell media (MSCM) consisting of high glucose (4.5 g/l) Dulbecco's Modified Eagle's Medium (DMEM) (Thermo Fisher Scientific) supplemented with 10% FBS and 1% P/S.

Preparation of Cardiosphere-Derived Cells

Atrial tissue was minced into <1 mm³ explants and washed with Dulbecco's Phosphate-Buffered Saline (DPBS) (Thermo Fisher Scientific). The explants were digested in 0.2% trypsin and 0.1% collagenase IV (both from Thermo Fisher Scientific) three times for 5 min each at 37°C. After the final digestion, explants were placed in 5 ml of CEM for 5 min and then transferred onto fibronectin (Thermo Fisher Scientific) coated 25 cm² tissue culture flasks (Greiner Bio One) with 2–3 explants per flask. These were allowed to adhere for 30–60 min, after which 5–7 ml of CEM media was added and incubated in standard tissue culture conditions (37°C and 5% CO₂ in humidified air) to allow a stromal-like cell layer to emerge as an outgrowth from the explants over a period of 3–7 days, during which time phase-bright cells appeared above the cell monolayer (21,31,33). Cells were detached with TrypLE Express (Thermo Fisher Scientific) and plated at a density of $1 \times 10^5/\text{cm}^2$ on Ultra-Low Attachment flasks (ULA) (Corning) in CEM containing 10% FBS. Once cardiospheres had formed over 5–7 days, they were collected and seeded onto fibronectin coated flasks to yield cardiosphere-derived cells (CDCs) in CEM with 20% FBS. Cells were passaged at 60–80% confluence by washing twice with DPBS and incubating with 0.25% trypsin (Thermo Fisher Scientific) for 5 min in tissue culture conditions. Trypsin was inactivated by adding an equal volume of CEM and cells centrifuged at 400 g for 7 min. CDCs were cryopreserved in CellBanker 2 medium (AMS Biotechnology Ltd.) at a density of $1\text{--}2 \times 10^6/\text{ml}$ and temperature decrease of $-1^\circ\text{C}/\text{min}$ in a freezing container (Mr Frosty, Thermo Fisher Scientific) to -80°C . CDCs were transferred to liquid nitrogen storage after 24 h.

Preparation of Mesenchymal Stem Cells

Canine adipose-derived mesenchymal stem cells (MSCs) were isolated as previously described (34–36). This cell type was used for comparison since they can be readily obtained, cultured, and is the most comprehensively characterized canine adult stem cell. Briefly, tissue samples were washed twice with 5 ml of DPBS, finely minced with scissors and then incubated with 0.2% collagenase IV at 37°C with mild agitation (40 rpm) for 45 min. The resulting suspension was filtered through a 70 μm nylon cell strainer (Corning) and centrifuged at 1,000 g for 10 min. The supernatant was discarded and the cell pellet re-suspended in 1 ml of MSCM. Cells were counted by Trypan blue (Sigma-Aldrich) dye exclusion and seeded onto 25 cm² tissue culture flasks at a density of $3\text{--}5 \times 10^4$ cells/cm². These were incubated in tissue culture conditions. After 24 h unattached cells were removed with two DPBS washes. Cells were passaged and cryopreserved as

described for CDCs. Both fresh and cryopreserved MSCs were used for analysis, since cryopreservation has been shown to not alter their stem characteristics (37).

Cellular assays were performed on at least three donor (biological) samples with three technical replicates for each donor sample.

Antibody Staining for Flow Cytometry

Cryopreserved cells were rapidly thawed at 37°C, re-suspended in appropriate growth media, washed once by centrifugation at 400 g for 7 min and cultured in the same conditions as fresh cells for 3–5 days prior to antibody staining. Fresh cells were used directly from tissue culture vessels. Cells were detached by washing twice with DPBS and incubating at 37°C with Accutase (Thermo Fisher Scientific). Recovered cells were pelleted by centrifugation (400 g for 5 min at 20°C), pellets were washed with chilled (4°C) FACS buffer (FACSFlow; BD Biosciences), re-suspended at a concentration of 3×10^6 /ml in FACS buffer and 100 µl aliquots transferred into FACS tubes (Thermo Fisher Scientific). Monoclonal antibodies or isotope-matched controls were added to each tube and incubated for 30 min at 4°C protected from light. Cells were pelleted by centrifugation at 400 g for 5 min at 4°C, washed by re-suspension in FACS buffer and suspended in 1 ml of FACS buffer for acquisition. The antibodies used were anti-canine CD90 (eBioscience, clone YKIX337.217, 1:20 dilution), anti-mouse CD105 (BD Biosciences, clone MJ7/18, 1:10), anti-human CD44 (Biolegend, clone IM7, 1:20), anti-human CD29 (BD Bioscience, clone MAR4, 1:20), anti-canine CD34 (R&D Systems, clone IH6, 1:10), anti-canine CD45 (Bio-rad, clone YKIX716.13, 1:10), and anti-human CD117 (BD Bioscience, clone YB5.B8, 1:10). Isotype controls were mouse IgG1 for CD34, CD29, and CD117 (BD Bioscience, clone MOPC-21, 1:10), rat IgG2b for CD90, CD45, and CD44 (eBioscience, clone eB149/10H5, 1:10) and rat IgG2a for CD105 (BD Biosciences, clone R35–95, 1:10). Antibodies were conjugated with R-phycoerythrin.

Flow Cytometry

Samples were acquired in polystyrene FACS tubes on a BD FACS Calibur flow cytometer (BD Bioscience). The instrument was calibrated using CaliBRITE 3 color FACS Comp beads (BD Bioscience) before acquiring and analyzing each set of samples using CellQuest Pro software (BD biosciences). Unlabeled cells were acquired in order to set the forward and side scatter parameters to center the cell population on the scatter plot. Fluorescence intensity was adjusted to set the unlabeled cells within 10^0 – 10^1 on the log scale axis. Cells were then acquired with an event count set to a total of 1×10^4 events. Data was analyzed using FlowJo software (FlowJo, LLC). Further details are provided in MIFlowCyt (Supporting Information).

Population Doubling Time

Freshly prepared CDCs and MSCs (non-cryopreserved), and cryopreserved CDCs were assessed for growth kinetics using a population doubling time protocol (PDT) as previously described (35). Cryopreserved cells were expanded for

3–5 days in tissue culture vessels as described above prior to the PDT protocol. Briefly, cells were detached from culture vessels using 0.25% trypsin, pelleted and counted by Trypan blue dye exclusion. 1×10^4 cells suspended in CEM (CDCs) or MSCM (MSCs) were plated per well, in six-well plates, in triplicate for each cell type and each time point. Cells were detached with trypsin every 3–4 days for two weeks to perform cell counts. The doubling time was calculated according to the formula $PDT = \ln(N/N_0)/\ln 2$ where N was the final cell number and N_0 was the cell number at the beginning of the logarithmic increase.

Clonal Growth Assay

CDCs were trypsinized from culture vessels, counted and plated at very low density (20 cells/cm²) on fibronectin coated 25 cm² flasks. After 24 h individual cells were visualized on an Olympus inverted microscope (model CKX415F; Olympus Corporation). The culture vessel was observed daily for 10 days to identify the formation of colonies. Cells were discounted from analysis if more than one cell was present in the field of view of a low power objective lens (4 x magnification objective) at the start of the culture period. Images were captured with a color digital camera (GT Vision Ltd.). Colony size was measured using ImageJ software version 1.50i (National Institute of Health).

Sphere Size Assessment

To assess the diameter of spheres formed from fresh CDCs and cryopreserved CDCs, cells were seeded at a density of 1×10^5 /cm² on an ULA surface. The spheres formed were tracked with culture time and sphere number and diameter measured at 5 days using ImageJ software. These parameters were compared to primary spheres that were formed by fresh CDCs at the same time point as detailed above in the preparation of cardiosphere-derived cells section.

Differentiation Capacity of CDCs and MSCs

MSCs were induced to differentiate toward osteogenic, adipogenic (26–28), or smooth muscle (14) lineages as previously reported.

Osteogenic differentiation. MSCs were plated in six-well plates (5,000 cell/cm²) and cultured to 80% confluence before induction. Osteogenic induction medium consisted of DMEM with 10% FBS supplemented with dexamethasone (100 nM), ascorbic acid (0.2 mM) and β-glycerophosphate (10 mM) (all from Sigma-Aldrich) with P/S. Medium was changed every 2–3 days. After 14 days of induction, extracellular calcium deposits were assessed using 2% Alizarin Red S (Sigma-Aldrich) staining at pH 4.3.

Adipogenic differentiation. MSCs were plated in six-well plates (8,000 cell/cm²) and cultured to 90–100% confluence before induction. Induction wells were subjected to alternating cycles of inductive medium (72 h) followed by maintenance medium (24 h) repeated six times. Inductive medium consisted of DMEM with 10% FBS supplemented with dexamethasone (1 µM), 1% insulin, indomethacin (100 µM), 3-

ORIGINAL ARTICLE




Figure 1. Representative photomicrographs showing the formation of cardiosphere-derived cells (CDCs) and mesenchymal stem cells (MSCs). Panel (A) stromal-like outgrowth cells from an atrial tissue explant with phase-bright cells (long arrows) migrating over the spindle-like cell monolayer. The phase-bright cells were harvested and further grown in suspension culture to form cardiospheres (B). Heterogeneous sized cardiospheres were typically formed. Cardiospheres were collected by aspiration and seeded on fibronectin-coated tissue culture plastic to form cardiosphere-derived cells (CDCs) which are the fibronectin adherent population emerging from the cardiosphere (C) and shown at higher magnification (D). CDCs that were cultured following cryopreservation (E) had a similar morphology to fresh CDCs (D). The CDC population typically contained a mixture of spindle-like cells (white arrows) among more rounded cells (black arrows). These are representative results for atrial tissue from five dogs. MSCs showed typical spindle-like cell morphology (F). Scale bars = 250 μ m.

isobutyl-1-methylxanthine (100 μ M) (all Sigma-Aldrich) with P/S. Oil-Red-O staining was used to assess intracytoplasmic lipid accumulation.

Smooth muscle and endothelial differentiation. Fresh CDCs, MSCs, and cryopreserved CDCs were seeded onto fibronectin-coated Nunc Lab-Tek chamber slides (Thermo Fisher Scientific), allowed to reach 80% confluence and subjected to differentiation media for 12–13 days. Smooth muscle differentiation media consisted of IMDM with 1% L-glutamine, 1% P/S and 10 ng/ml platelet-derived growth factor- β (PDGF- β , Preprotech; 100–14B). Endothelial differentiation media consisted of IMDM with 1% L-glutamine, 1% P/S and 50 ng/ml vascular endothelial growth factor (VEGF, Preprotech; 100–20 A). Immunocytochemistry was performed to assess formation of actin fibers or expression of von Willebrand factor (vWF).

Cardiomyocyte differentiation. Following monolayer culture, fresh CDCs and cryopreserved CDCs were dissociated and seeded at a density of $1 \times 10^5/\text{cm}^2$ on either 24 or 6 well plates on a cell-repellent surface (Greiner Bio One) to form secondary cardiospheres. Once spheres had formed (3–5 days), media in inductive wells was changed to Cardiomyocyte Differentiation Kit media according to the manufacturers instructions (Thermo Fisher Scientific) and continued for 12–14 days. Next, spheres were harvested and attached to FBS-

coated chamber slides for 18 h. Expression of cardiac troponin T (cTNT) was assessed by immunocytochemistry. Expression of cTNT was also assessed on individual cells as described for smooth muscle and endothelial differentiation.

Immunocytochemistry

Following termination of differentiation, cells were fixed in 4% PFA for 10 min then blocked and permeabilized in protein block solution (DAKO) containing 1% saponin (Sigma-Aldrich) for 1.5 h. Cells were incubated at 4°C with a primary antibody for 1 h then secondary antibodies for 1 h. The primary antibodies used were: monoclonal mouse anti-cardiac troponin T (Abcam, clone 1C11; 1:500 dilution), mouse anti-smooth muscle actin (Sigma-Aldrich, clone 1A4; 1:200) and polyclonal rabbit anti-von Willebrand factor (Abcam, 1:400). Fluorescein isothiocyanate (FITC) labelled secondary antibodies were purchased from Abcam (polyclonal goat anti-mouse IgG, 1:500) and Biologend (polyclonal donkey anti-rabbit IgG, 1:250). Control slides consisted of unstained cells, undifferentiated cells and secondary antibody only stained slides. Slides were mounted with Vectashield containing 4', 6-diamidino-2-phenylindole (DAPI) (Vector Laboratories Ltd). Cells were visualized with an Olympus BX60 microscope (Olympus Corporation) equipped with a CoolLED pE-2 fluorescence illumination system (CoolLED Ltd.) and images captured using a QImaging QICAM digital camera.




Figure 2. Comparison of growth characteristics of canine cardiosphere-derived cells (CDCs). (A) Sphere diameters of primary and secondary cardiospheres obtained from fresh cells and from cryopreserved cells. Secondary spheres were significantly smaller than primary spheres and spheres obtained from cryopreserved CDC were significantly larger than either primary or secondary spheres. (B) There was no significant difference in the PDT between fresh and cryopreserved cells but both were significantly slower compared to canine adipose MSCs. (C) Colony diameter for fresh and cryopreserved CDCs plated at low density. Colony size measurements shown were taken at days 4 and 7 and showed no significant difference between the two cell populations on either day. (D) Clonal expansion of CDCs from both fresh and cryopreserved cells. Scale bars = 250 μ m.

Statistical Analysis

GraphPad Prism 7 software (GraphPad Software Inc. CA, USA) was used for statistical analysis. Data was assessed for normality. All data is presented as the mean \pm SEM unless stated otherwise. Comparisons between two independent samples were performed using student's two-tailed *t* test and between three or more groups using one-way ANOVA with post hoc Tukey analysis. A *P* values of < 0.05 was considered significant.

RESULTS

Cardiosphere Formation

CDCs were isolated and expanded from dogs ($n = 5$) of different breeds or of non-pedigree origin. Donor characteristics are summarized in Supporting Information Table S1. Within 5–7 days a stromal-like monolayer of cells emerged from the explants above which phase-bright cells migrated (Fig. 1A). The phase-bright cells formed spheres (Fig. 1B). Early passage CDCs showed a heterogeneous population of cell morphologies consisting of both long spindle shaped cells and rounded cells (Fig. 1C,D). CDCs had a post-

cryopreservation viability of 95–98% after being frozen for 3 months and could be further expanded in monolayer culture on fibronectin-coated flasks. Culture expanded cells showed a similar heterogeneous morphology (Fig. 1E). By comparison MSCs prepared from adipose tissue showed typical spindle shaped cells, which were homogeneous in morphology (Fig. 1F).

Cardiosphere Characteristics

Both cryopreserved and non-cryopreserved CDCs were able to readily form into secondary cardiospheres when plated onto a low attachment surface. The diameter of primary, secondary and cryopreserved cardiospheres was compared. Secondary spheres formed by fresh CDCs were 20% smaller than primary spheres (Fig. 2A; $P < 0.0001$). Strikingly, the spheres formed by cryopreserved cells were approximately three times larger than those formed from fresh CDCs (Fig. 2A; $P < 0.0001$).

Population Doubling and Cloning Potential

The cloning potential and growth kinetics were assessed for CDCs prior to and after cryopreservation. The population doubling time was similar between the two groups (Fig. 2B;

ORIGINAL ARTICLE




Figure 3. Cardiac, smooth muscle, and endothelial differentiation. Fresh and cryopreserved canine cardiosphere-derived cells (CDCs) demonstrated expression of cardiac troponin T (cTNT, green fluorescence) following repeat sphere formation in the presence of cardiomyocyte differentiation medium (A–I). Individual CDCs for the majority showed disorganized cTNT protein (J), although a small number of cells showed an early-striated fiber pattern (K). CDCs were also able to differentiate toward a smooth muscle lineage as shown by expression of alpha-smooth muscle actin (α -SMA, green fluorescence) when compared to control cells (L and M), this ability was unaffected by cryopreservation (N). Expression of von Willebrand factor (vWF, green fluorescence) demonstrating a commitment to the endothelial lineage in fresh and cryopreserved cells (O–Q). MSCs showed marked up-regulation of α -SMA on induction when compared to control cells (P and Q). Nuclei are counterstained with DAPI (blue fluorescence). Scale bars = 50 μ m (D–I and K) 25 μ m (other panels).

fresh vs. cryopreserved; 57.13 ± 5.27 h vs. 48.94 ± 9.55 h, $P = 0.71$). As a comparison, canine MSCs had a significantly faster population doubling time compared to both fresh and cryopreserved CDC (Fig. 2B; 30.46 h, $P < 0.05$). There was no significant difference in the diameter of clonal colonies between the two groups by Day 7 (Fig. 2C; fresh versus cryopreserved; 1.30 ± 0.19 mm versus 1.20 ± 0.13 mm, $P = 0.73$). Both cell populations were able to form clonal colonies from single cells when plated at very low density (Fig. 2D).

Multipotency of CDCs and MSCs

When fresh and cryopreserved CDCs were placed into suspension culture to form secondary cardiospheres, they expressed high levels of troponin T within their cytoplasm following induction with a cardiomyocyte medium (Fig. 3A–I). In addition, single plated CDCs showed cytoplasmic troponin T staining that was mostly disorganized (Fig. 3J), but a small number of cells demonstrated early fiber alignment and striation (Fig. 3K). Both fresh and cryopreserved CDCs also demonstrated capacity for differentiation toward lineages of

endothelium (positive expression of vWF) and smooth muscle (positive expression of α -smooth muscle actin, Fig. 3L–Q). MSCs also differentiated into a smooth muscle phenotype when induced with PDGF- β and expressed smooth muscle actin (Fig. 3R,S) and showed positive staining for Alizarin Red S and Oil Red O following induction in osteogenic or adipogenic medium, respectively, when compared to control cells (Fig. 4A–D).

Surface Marker Expression Profile

Flow cytometry analysis showed fresh CDCs consisted of a high proportion of CD105⁺ ($89.0\% \pm 4.98$) and CD44⁺ ($99.68\% \pm 0.13$) cells, low proportions of CD90⁺ ($23.36\% \pm 9.78$), CD117⁺ ($13.17\% \pm 8.67$), CD29⁺ ($2.92\% \pm 2.46$) cells, and a negligible proportion of CD45⁺ cells ($0.005\% \pm 0.003$, Fig. 5A–F). In contrast MSCs showed a high proportion of CD90⁺ ($99.60\% \pm 0.30$), CD44⁺ ($99.85\% \pm 0.05$), and CD105⁺ ($76.55\% \pm 22.35$) cells and a small fraction of CD34⁺ cells ($1.80\% \pm 1.76$). CD117⁺ ($0.92\% \pm 0.34$), CD45⁺ ($0.015\% \pm 0.005$), and CD29⁺ ($0.57\% \pm 0.46$) cells represented a very




Figure 4. Adipogenic and osteogenic differentiation of mesenchymal stem cells (MSCs). Photomicrographs depicting Alizarin Red S staining for osteogenic differentiation: (A) control (non-induced) cells and (B) induced cells showing positive red staining for mineral deposition. Oil Red O staining for adipogenic differentiation: (C) control (non-induced) cells, (D) induced cells showing intracellular deposits of red stained oil droplets. Images are representative of differentiation of cells derived from five dogs. Scale bar = 250 μ m.

small fraction (Fig. 5M–R). Interestingly, the percentage of CD34⁺ cells was variable with passage number with low percentages in low passage CDCs (P1–2; 7.18% \pm 4.03) but increased to moderate and high percentages with further passaging (P4–5

59.75% \pm 3.45, P = 0.003, Fig. 6A–C), with high percentages following cryopreservation (79.35% \pm 4.85, Fig. 6D). This was in contrast to the proportion of CD90⁺ cells, which was higher in unpassaged cells (P0; 42.55% \pm 13.65) but decreased in P4–5

F6




Figure 5. Flow cytometry contour plots for surface marker expression analysis of cardiosphere-derived cells (CDCs) and mesenchymal stem cells (MSCs). CDCs show intermediate proportions of CD90⁺ cells (A), negligible CD45⁺ cells (B), high proportion of CD44⁺ cell (C), low numbers of CD117⁺ cells (D), intermediate to high CD34⁺ cell percentage (E) and high CD105⁺ cell portion (F). MSCs showed a high percentage of CD90⁺ cells (G), low proportion of CD45⁺ cells (H), high CD44⁺ proportion (I), negligible CD117⁺ (J) and CD34⁺ proportion (K), and a high CD105⁺ proportion (L). Blue contours denote isotype control and red contours denote antibody labeled samples. Antibodies were R-PE conjugated.

ORIGINAL ARTICLE




Figure 6. Flow cytometry comparing CD34 and CD90 expression on cardiosphere-derived cells (CDCs) at different passages and post-cryopreservation. CD34⁺ cells were negligible in P0 cells (A; 1.1%) but increased from P1 to P4 (B and C, 14.8% and 55.3%). Cryopreserved cells showed a high CD34⁺ proportion (D, 84.2%). Conversely the CD90⁺ portion was reduced with passage number. P0 CDCs showed a high CD90⁺ percentage (E, 56.2%) and 50.7% at P1 (F), and 28.9% at P4 (G). CD90 was absent in cryopreserved CDCs (H). Blue contours denote isotype control and red contours denote antibody labeled samples.

(15.04% \pm 9.77, $P = 0.03$, Fig. 6E–G). The CD90⁺ fraction was low in CDCs following cryopreservation (3.03% \pm 1.41, Fig. 6H). Other markers (CD105, CD44, CD45, CD117, and CD29) exhibited a similar expression profile between fresh and cryopreserved CDCs.

DISCUSSION

In this study, we derived CDCs from multiple donor animals for characterization prior to and following cryopreservation, since to the authors knowledge the effect of freezing on CDCs has not been assessed in any species. Understanding the effect of cryopreservation on these cells is vital for conducting clinical trials using frozen CDCs. The effect of cryopreservation is well characterized for MSCs (37,38); however, previous attempts in our laboratory to freeze canine cardiac stem cells suggested they may be more labile than MSCs to cryopreservation. We utilized atrial tissue as previous reports indicated a higher number of c-Kit⁺ cells present within the atria and therefore potentially a greater number of cardiac stem cells may be obtained compared to the ventricle (17,24). Atrial tissue has also been used previously to isolate canine cardiac stem cells (33). We demonstrate for the first time that cryopreservation of canine CDCs does not affect their vital stem cell characteristics. First, there were no significant differences in clonal growth and population doubling characteristics suggesting that CDCs tolerate freezing. The ability of CDCs to differentiate was also unaffected since they were able to express α -smooth muscle actin, von Willebrand factor and troponin T indicating commitment to the smooth muscle, endothelial and cardiomyocyte lineages, respectively, as reported by others for fresh cells (25,31). Furthermore, fresh

and cryopreserved CDCs demonstrated cardiomyogenic potential following secondary sphere formation and culture in the presence of cardiomyocyte differentiation media. Cytological staining on individual cells shows mostly an immature troponin organization, although a small fraction of cells demonstrated a more complex organization, characterized by the emergence of a striated pattern.

Conversely, the process of cryopreservation did alter the proportions of certain cell surface markers. Specifically, the CD34⁺ fraction was increased after culture of cryopreserved CDCs. CD34, a transmembrane phosphoglycoprotein, is found on a diverse range of cells and appears to have multiple functions. It has been associated with cell-cell adhesion and highly proliferative cells (39–41). CD34 is often used as an exclusion criteria for MSCs (42), however a more recent literature review indicates its presence on some MSC populations (specifically adipose derived MSCs) and is expressed by a diverse range of other progenitor cells (43). The higher proliferative capacity of the CD34⁺ population (34–36) may explain the increase we observed with passage number and following cryopreservation. CD34⁺ cells also appear highly tolerant to freezing when compared to other nucleated cell types and therefore may have better survival in the heterogeneous CDC population (44). This may have clinical relevance as experiments in animal models of myocardial infarction using CD34⁺ purified cell populations showed an increased cellular persistence within the myocardium and showed positive effects on heart function (45,46).

In comparison with other species, early passage (P2) human CDCs exhibit a similar CD34⁺ population (approximately 10%) (47). However, another study reported fewer

CD34⁺ cells (1%) in human CDCs of undefined passage number (48). It has also been noted that increasing media serum content from 10% to 20% increases the CD34⁺ population from 0.9% to 7.5% (31). Cardiac progenitor cells grown directly from rat heart explants (without the cardiosphere step) declined in their CD34⁺ population over a culture period of 35 days (23).

Furthermore, there were varying proportions of CD90⁺ cells, which was both inter-donor (the variability between donors) and intra-donor dependent (the variability within a donor, dependent on culture conditions). The CD90⁺ fraction also decreased following cryopreservation and increasing passage number of fresh cells. CD90 (Thymocyte antigen-1; Thy-1) is a commonly used marker for MSCs in all reported species, including canines (35,49–51). The CD90⁺ population in our CDC preparations exists as a small fraction, as noted by others (20,29,45). Our finding that the CD90 population can be manipulated by passaging or cryopreservation may have clinical implications as this population appeared to reduce the therapeutic efficacy of CDCs in a rodent model of myocardial infarction (24).

Cryopreserved CDCs formed cardiospheres that were approximately three times larger than their fresh counterparts. This may be due to the higher CD34⁺ fraction increasing the cell-cell adhesion efficiency. Alternatively this may be an integrin dependent interaction as this has previously been shown to significantly increase the adherence and cell-cell binding in MSCs (52). This may be clinically relevant as the larger size could predispose them to arteriole blockage and subsequent tissue ischemia. Sphere size would therefore need to be controlled by the use of aggregation wells (53).

In comparison with other species, canine CDCs exhibit remarkable phenotypic similarities to mouse, rat, human, and porcine cells (21,22,28,54,55). As we elucidated in the introduction, canines are a unique naturally occurring model for non-ischemic cardiomyopathy in humans, specifically ARVC (8–10). The effect of cryopreservation on human CDCs is poorly understood; therefore given the similarities with canine cells the present study also provides vital translational information to the human field. Also phenotypically the sphere size formed from fresh cells is similar to reports in other species (21,31), conversely the large spheres from cryopreserved cells has not been noted previously. There are other notable differences. Firstly, differentiation of canine CDCs to functioning cardiomyocytes appears challenging. Methods attempting to translate mouse and rat differentiation protocols to canine cells have proved only partially successful (25,33). We also found similar difficulties in using cardiac differentiation media designed for mouse and human iPSCs. Additionally the c-Kit⁺ proportion in our atrial derived CDCs was higher than that reported in mouse, human and canine ventricular derived CDCs (22,23,25,30,31). C-Kit⁺ cells have been reported to be localized in areas within the heart with low hemodynamic stress, such as the atria in humans (17,18,56). The location of c-Kit expressing cells in the canine heart has not been described but the tissue compartment (atria) source likely explains the greater c-Kit⁺ population in

our CDCs. Previous studies with canine CDCs have examined ventricular tissue from a single donor (25,30) which limits the comparative interpretation with our study.

In conclusion, we conduct for the first time phenotypic analysis of CDCs prior to and following cryopreservation. Our most important finding is that the key stem characteristics of these cells are unchanged by this process. Changes were noted in the populations of cells expressing CD34 and CD90; however, the clinical significance of this is unknown, but based on previous literature could be beneficial. Our results show promise for the creation of cryopreserved cell banks for usage in future clinical trials.

CONFLICT OF INTEREST

The authors have declared no conflict of interest.

ACKNOWLEDGMENTS

This study was funded by The PetPlan Charitable Trust (Project number: 214–252). Royal Veterinary College manuscript approval number CSS_01545.

LITERATURE CITED

- Egenwall A, Bonnett BN, Häggström J. Heart disease as a cause of death in insured Swedish dogs younger than 10 years of age. *J Vet Intern Med* 2006;20:894–903.
- Simpson S, Dunning MD, Brownlie S, Patel J, Godden M, Cobb M, et al. Multiple genetic associations with Irish Wolfhound dilated cardiomyopathy. *BioMed Res Int* 2016;2016:14. Article ID 6374082.
- Simpson S, Edwards J, Ferguson-Mignan TFN, Cobb M, Mongan NP, Rutland CS. Genetics of human and canine dilated cardiomyopathy. *Int J Genomics* 2015;2015: 204823.
- Simpson S, Edwards J, Emes RD, Cobb MA, Mongan NP, Rutland CS. A predictive model for canine dilated cardiomyopathy—a meta-analysis of Doberman Pinscher data. *PeerJ* 2015;3:e842.
- Meurs KM, Stern JA, Sisson DD, Kittleson MD, Cunningham SM, Ames MK, et al. Association of dilated cardiomyopathy with the striatin mutation genotype in boxer dogs. *J Vet Intern Med* 2013;27:1437–1440.
- Mausberg TB, Wess G, Simak J, Keller L, Drögemüller M, Drögemüller C, et al. A locus on chromosome 5 is associated with dilated cardiomyopathy in Doberman pinschers. *PLoS One* 2011;6:5–10.
- Tidholm A, Jönsson L, Jonsson L. Histologic Characterization of Canine Dilated Cardiomyopathy. *Vet Pathol* 2005;42:1–8.
- Basso C, Fox PR, Meurs KM, Towbin JA, Spier AW, Calabrese F, et al. Arrhythmogenic right ventricular cardiomyopathy causing sudden cardiac death in boxer dogs: A new animal model of human disease. *Circulation* 2004;109:1180–1185.
- Vila J, Pariaut R, Moise NS, Oxford EM, Fox PR, Reynolds CA, et al. Structural and molecular pathology of the atrium in boxer arrhythmogenic right ventricular cardiomyopathy. *J Vet Cardiol* 2017;19:57–67.
- Oxford EM, Danko CG, Fox PR, Kornreich BG, Moise NS. Change in β -Catenin localization suggests involvement of the canonical wnt pathway in boxer dogs with arrhythmogenic right ventricular cardiomyopathy. *J Vet Intern Med* 2014;28:92–101.
- Yamada N, Kitamori T, Kitamori F, Ishigami K, Iwanaga K, Itou T, et al. Arrhythmogenic right ventricular cardiomyopathy coincided with the cardiac fibrosis in the inner muscle layer of the left ventricular wall in a boxer dog. *J Vet Med Sci* 2015;77: 1299–1303.
- Meurs KM, Stern JA, Reina-Doreste Y, Spier AW, Kopitz SL, Baumwart RD. Natural History of Arrhythmogenic Right Ventricular Cardiomyopathy in the Boxer Dog: A Prospective Study. *J Vet Intern Med* 2014;28:1214–1220.
- Saffitz JE. Desmosome mutations in arrhythmogenic right ventricular cardiomyopathy important insight but only part of the picture. *Circ Cardiovasc Genet* 2009;2: 415–417.
- Wess G, Schulze A, Butz V, Simak J, Killich M, Mauerer J, et al. Prevalence of dilated cardiomyopathy in Doberman pinschers in various age groups. *J Vet Intern Med* 2010;24:533–538.
- Nadal-Ginard B, Kajstura J, Leri A, Anversa P. Myocyte death, growth, and regeneration in cardiac hypertrophy and failure. *Circ Res* 2003;92:139–150.
- Condorelli G, Borello U, De Angelis L, Latronico M, Sirabella D, Coletta M, et al. Cardiomyocytes induce endothelial cells to trans-differentiate into cardiac muscle: Implications for myocardium regeneration. *Proc Natl Acad Sci USA* 2001;98:10733–10738.
- He JQ, Vu DM, Hunt G, Chugh A, Bhatnagar A, Bolli R. Human cardiac stem cells isolated from atrial appendages stably express c-kit. *PLoS One* 2011;6
- Hosoda T. C-kit-positive cardiac stem cells and myocardial regeneration. *Am J Cardiovasc Dis* 2012;2:58–67.

AQ3

AQ4

AQ6 AQ5

AQ7

ORIGINAL ARTICLE

19. Genead R, Danielsson C, Wårdell E, Kjældgaard A, Westgren M, Sundström E, et al. Early first trimester human embryonic cardiac Islet-1 progenitor cells and cardiomyocytes: Immunohistochemical and electrophysiological characterization. *Stem Cell Res* 2010;4:69–76.
20. Matsuura K, Nagai T, Nishigaki N, Oyama T, Nishi J, Wada H, et al. Adult cardiac Sca-1-positive cells differentiate into beating cardiomyocytes. *J Biol Chem* 2004;279:11384–11391.
21. Messina E, De Angelis L, Frati G, Morrone S, Chimenti S, Fiordaliso F, et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. *Circ Res* 2004;95:911–921.
22. Chimenti I, Smith RR, Li TS, Gerstenblith G, Messina E, Giacomello A, et al. Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. *Circ Res* 2010;106:971–980.
23. Davis DR, Kizana E, Terrovitis J, Barth AS, Zhang Y, Smith RR, et al. Isolation and expansion of functionally-competent cardiac progenitor cells directly from heart biopsies. *J Mol Cell Cardiol* 2010;49:312–321.
24. Cheng K, Ibrahim A, Hensley MT, Shen D, Sun B, Middleton R, et al. Relative roles of CD90 and c-Kit to the regenerative efficacy of cardiosphere-derived cells in humans and in a mouse model of myocardial infarction. *J Am Heart Assoc* 2014;3:e001260.
25. Hensley MT, de Andrade J, Keene B, Meurs K, Tang J, Wang Z, et al. Cardiac regenerative potential of cardiosphere-derived cells from adult dog hearts. *J Cell Mol Med* 2015;19:1805–1813.
26. Johnston PV, Sasano T, Mills K, Evers R, Lee S, Smith RR, et al. Engraftment, differentiation and functional benefit of autologous cardiosphere-derived cells in a porcine ischemic cardiomyopathy. *Circulation* 2009;120:1075–1083.
27. Kanazawa H, Tseliou E, Dawkins JF, De Couto G, Gallet R, Malliaras K, et al. Durable benefits of cellular postconditioning: Long-term effects of allogeneic cardiosphere-derived cells infused after reperfusion in pigs with acute myocardial infarction. *J Am Heart Assoc* 2016;5:1–16.
28. Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LEJ, Berman D, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): A prospective, randomised phase 1 trial. *Lancet* 2012;379:895–904.
29. Malliaras K, Makkar RR, Smith RR, Cheng K, Wu E, Bonow RO, et al. Intracoronary cardiosphere-derived cells after myocardial infarction: Evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CARDiosphere-derived autologous stem CELLS to reverse ventricular dysfunction). *J Am Coll Cardiol* 2014;63:110–122.
30. Hensley MT, Tang J, Woodruff K, Defrancesco T, Tou S, Williams CM, et al. Intracoronary allogeneic cardiosphere-derived stem cells are safe for use in dogs with dilated cardiomyopathy. *J Cell Mol Med* 2017;1–10.
31. Davis DR, Zhang Y, Smith RR, Cheng K, Terrovitis J, Malliaras K, et al. Validation of the cardiosphere method to culture cardiac progenitor cells from myocardial tissue. *PLoS One* 2009;4:e7195.
32. Cho H-J, Lee H-J, Youn S-W, Koh S-J, Won J-Y, Chung Y-J, et al. Secondary sphere formation enhances the functionality of cardiac progenitor cells. *Mol Ther* 2012;20:1750–1766.
33. Hodgkiss-Geere HM, Argyle DJ, Corcoran BM, Whitelaw B, Milne E, Bennett D, et al. Characterisation and cardiac directed differentiation of canine adult cardiac stem cells. *Vet J* 2012;191:176–182.
34. Kisiel AH, McDuffee LA, Masaoud E, Bailey TR, Esparza Gonzalez BP, Nino-Fong R. Isolation, characterization, and in vitro proliferation of canine mesenchymal stem cells derived from bone marrow, adipose tissue, muscle, and periosteum. *Am J Vet Res* 2012;73:1305–1317.
35. Screven R, Kenyon E, Myers MJ, Yancy HF, Skasko M, Boxer L, et al. Immunophenotype and gene expression profile of mesenchymal stem cells derived from canine adipose tissue and bone marrow. *Vet Immunol Immunopathol* 2014;161:21–31.
36. Takemitsu H, Zhao D, Yamamoto I, Harada Y, Michishita M, Arai T. Comparison of bone marrow and adipose tissue-derived canine mesenchymal stem cells. *BMC Vet Res* 2012;8:150.
37. Martinello T, Bronzini I, Maccatrozzo L, Mollo A, Sampaoli M, Mascarello F, et al. Canine adipose-derived-mesenchymal stem cells do not lose stem features after a long-term cryopreservation. *Res Vet Sci* 2011;91:18–24.
38. Marquez-Curtis LA, Janowska-Wieczorek A, McGann LE, Elliott JAW. Mesenchymal stromal cells derived from various tissues: Biological, clinical and cryopreservation aspects. *Cryobiology* 2015;71:181–197.
39. Healy L, May G, Gale K, Grosfeld F, Greaves MET. The stem cell antigen CD34 functions as a regulator of hemopoietic cell adhesion. *Proc Natl Acad Sci USA*. 1995;92:12240–12244.
40. Huss R. Isolation of primary and immortalized CD34-hematopoietic and mesenchymal stem cells from various sources. *Stem Cells* 2000;18:1–9.
41. Servida F, Soligo D, Caneva L, Bertolini F, Harven E, De Campiglio S, et al. Functional and Morphological Characterization of Immunomagnetically Selected CD34⁺ Hematopoietic Progenitor Cells. *Stem Cells* 1996;430–438.
42. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 2006;8:315–317.
43. Sidney LE, Branch MJ, Dunphy SE, Dua HS, Hopkinson A. Concise review: Evidence for CD34 as a common marker for diverse progenitors. *Stem Cells* 2014;32:1380–1389.
44. Moezzi L, Pourfathollah AA, Alimoghaddam K, Soleimani M, Ardjmand AR. The effect of cryopreservation on clonogenic capacity and in vitro expansion potential of umbilical cord blood progenitor cells. *Transplant Proc* 2005;37:4500–4503.
45. Wang J, Zhang S, Rabinovich B, Bidaut L, Soghomonian S, Alauddin MM, et al. Human CD34⁺ cells in experimental myocardial infarction: Long-term survival, sustained functional improvement, and mechanism of action. *Circ Res* 2010;106:1904–1911.
46. Botta R, Gao E, Stassi G, Bonci D, Pelosi E, Zwas D, et al. Heart infarct in NOD-SCID mice: Therapeutic vasculogenesis by transplantation of human CD34⁺ cells and low dose CD34⁺KDR⁺ cells. *FASEB J* 2004;18:1392–1394.
47. Smith RR, Barile L, Cho HC, Leppo MK, Hare JM, Messina E, et al. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. *Circulation* 2007;115:896–908.
48. Li TS, Cheng K, Malliaras K, Smith RR, Zhang Y, Sun B, et al. Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. *J Am Coll Cardiol* 2012;59:942–953.
49. Davies OG, Cooper PR, Shelton RM, Smith AJ, Scheven BA. Isolation of adipose and bone marrow mesenchymal stem cells using CD29 and CD90 modifies their capacity for osteogenic and adipogenic differentiation. *J Tissue Eng* 2015;6:1–10.
50. Comparing the osteogenic potential of canine mesenchymal stem cells derived from adipose tissues, bone marrow, umbilical cord blood, and Wharton's jelly for treating bone defects. *J Vet Sci* 2012;3:299–310.
51. Takemitsu H, Zhao D, Yamamoto I, Harada Y, Michishita M, Arai T. Comparison of bone marrow and adipose tissue-derived canine mesenchymal stem cells. *BMC Vet Res* 2012;8:150.
52. Clements LE, Garvican ER, Dudhia J, Smith RKW. Modulation of mesenchymal stem cell genotype and phenotype by extracellular matrix proteins. *Connect Tissue Res* 2016;57:443–453.
53. Cho HJ, Lee HJ, Chung YJ, Kim JY, Cho HJ, Yang HM, et al. Generation of human secondary cardiospheres as a potent cell processing strategy for cell-based cardiac repair. *Biomaterials* 2013;34:651–661.
54. Malliaras K, Li TS, Luthringer D, Terrovitis J, Cheng K, Chakravarty T, et al. Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells. *Circulation* 2012;125:100–112.
55. Poncellet AJ, Vercruysse J, Saliez A, Gianello P. Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo. *Transplantation* 2007;83:783–790.
56. Simpson DL, Mishra R, Sharma S, Goh SK, Deshmukh S, Kaushal S. A strong regenerative ability of cardiac stem cells derived from neonatal hearts. *Circulation* 2015;132:395–401.

AQ8

AQ9